Catalina Research Institute

Montclair, California 91763-2231

3 studies enrolling now · 29 studies all time

What they study most

Alzheimer Disease, Depressive Disorder, Major, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Drug Abuse, Fatty Liver, Hepatic Cirrhosis, Hyperlipidemia, Hypertension, Liver Fibrosis, MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)

Studies at this site

• "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" — Recruiting now
• An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1) — Recruiting now
• A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) — Recruiting now
• A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension — Completed
• A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease — Completed
• A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant — Completed
• A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen — Completed
• Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study) — Completed
• Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight — Running, not enrolling
• A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis — Stopped early
• HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes — Completed
• Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis — Running, not enrolling
• Safety and Efficacy Study of S-309309 in Obese Adults — Completed
• A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure — Completed
• Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH) — Completed
• Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis — Completed
• Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease — Completed
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients — Completed
• Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) — Completed
• ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) — Completed
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis — Completed
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis — Completed
• ARDA Software for the Detection of mtmDR — Completed
• Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease — Completed
• Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain — Stopped early
• The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus — Completed
• Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin — Stopped early
• Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM — Completed